2002 Access Clinical Trials 
Cannabis Law Report
JUNE 14, 2022
There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow. We will be joined by excellent speakers including Dr. Thomas Insel – Former Director of the US National Institute of Mental Health (2002 – 2015), Prof. David Nutt and Prof.
The Cannigma
MAY 17, 2022
A 2002 study found that smoking cannabis increased blood flow in the frontal lobe, an area that’s thought to play an important role in abstract thought, creative thinking and sensory processing. 15 Multiple clinical trials have shown that linalool in ylang ylang oil and lavender oil “significantly increased calmness.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
AUGUST 14, 2022
A 2002 study found that cannabis increases blood flow to the frontal lobe of the brain. 11 Multiple clinical trials have shown that linalool in ylang ylang oil and lavender oil, which are both high in linalool “significantly increased calmness” which can help an overactive brain settle down and focus.
The Cannigma
DECEMBER 12, 2022
Turning down activity in the DMN allows better access to new areas of the brain, which can boost creativity and improve problem solving. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. As such, there have been numerous clinical trials using ketamine.
Otherside Farms
JANUARY 23, 2019
Medscape: Medscape Access. news – 2002). abst – 2002). 2002 Feb-Mar] – PubMed result. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Cannabinoids and cancer: potential for colorectal cancer therapy. full – 2000).
Cannabis Law Report
JULY 25, 2022
Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. The charity was eventually instructed to pull an advertisement for the study by the ethics committee that conditionally approved the trial.
Cannabis Law Report
JULY 9, 2021
Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].
Expert insights. Personalized for you.
52 
Let's personalize your content